| Literature DB >> 32550593 |
Silvia A Camperi1,2, Gerardo Acosta3, Gabriela R Barredo1,2, Lucía C Iglesias-García1,2, Cleópatra Alves da Silva Caldeira1,2,4, María C Martínez-Ceron1,2, Silvana L Giudicessi1,2, Osvaldo Cascone1,2, Fernando Albericio3,5.
Abstract
Scorpion and spider envenomation is treated with the appropriate antivenoms, prepared as described by Césaire Auguste Phisalix and Albert Calmette in 1894. Such treatment requires the acquisition and manipulation of arachnid venoms, both very complicated procedures. Most of the toxins in the venoms of spiders and scorpions are extremely stable cysteine-rich peptide neurotoxins. Many strategies have been developed to obtain synthetic immunogens to facilitate the production of antivenoms against these toxins. For example, whole peptide toxins can be synthesized by solid-phase peptide synthesis (SPPS). Also, epitopes of the toxins can be identified and after the chemical synthesis of these peptide epitopes by SPPS, they can be coupled to protein carriers to develop efficient immunogens. Moreover, multiple antigenic peptides with a polylysine core can be designed and synthesized. This review focuses on the strategies developed to obtain synthetic immunogens for the production of antivenoms against the toxic Cys-rich peptides of scorpions and spiders.Entities:
Keywords: Carrier protein; Cysteine; Epitope; Epitopes; Immunogen conjugate; Knottins; Scorpion; Solid-phase peptide synthesis; Spider; Venom
Year: 2020 PMID: 32550593 PMCID: PMC7285918 DOI: 10.1016/j.toxcx.2020.100038
Source DB: PubMed Journal: Toxicon X ISSN: 2590-1710
Fig. 1A) Schematic representation of the inhibitor cystine knot or knottin: macrocycles are formed by CysI-CysIV and CysII-CysV disulfide bridges. The bridge between CysIII and CysVI crosses through a macrocycle, forming a knot-like structure. Loop regions are anchored to a core of anti-parallel β strands (arrows). B) Delta-ctenitoxin-Pn2a from Phoneutria nigriventer venom. Macrocycles are formed by Cys3-Cys17 and Cys10-Cys23 disulfide bridges. The bridge between Cys16 and Cys31 crosses through a macrocycle, forming a knot-like structure. This peptide also contains two more disulfide bridges between Cys14-Cys46 and Cys25-Cys29, which add further stability to the molecule.
Fig. 2Solid-phase peptide synthesis (SPPS): N-protected and side-chain protected amino acid (AA) is coupled to a solid phase () through a linker. After washing, the N-protected group (✪) is removed. The second N-protected amino acid is then coupled. Coupling (a) and deprotection (b) steps are repeated until the desired amino acid sequence has been elongated. Finally, side-chain protecting groups () are removed and the peptide is cleaved from the solid support (global deprotection) (c).
Fig. 3Scheme of native chemical ligation of two peptides obtained by solid-phase peptide synthesis. : Side-chain protecting group; :solid phase, :amino acid residue; Fmoc: 9-Fluorenylmethyloxycarbonyl; Fmoc-MeDbz-resin: 3-[(Fmoc)amino]-4-amino-benzoil resin; SPPS: solid-phase peptide synthesis; Me: methyl group; DIPEA: N,N-Diisopropylethylamine; TFA: Trifluoroacetic acid; GnHCl: Guanidinium chloride; and TCEP: Tris (2-carboxyethyl)phosphine hydrochloride.
Fig. 4Scheme of orthogonal Cys-rich peptide synthesis using different Cys protecting groups (▲).
Fig. 5Immunogen conjugate production by peptide epitope and carrier protein conjugation mediated by: A) 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl); B) N-hydroxysulfosuccinimide ester (NHS) crosslinker; and C) reactive sulfo-NHS ester and EDC.HCl; and D) NHS ester-maleimide heterobifunctional crosslinker sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC); E) glutaraldehyde.
Fig. 6Example of a Lys multiple antigenic peptide (MAP) with four copies of the antigenic peptide obtained by a dimerization through a Cys residue. : Amino acid residue.